Physician profile
Bobby Lee Paxton
NPI 1063844249
$2,327.56
in general payments reported to CMS, 2019-2025
18 companies · $529 in 2025
The $529 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $525 · 2023: $339 · 2024: $529 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.15 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.31 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $337.05 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $261.61 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $239.70 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $178.30 | 2021-2025 | |
| Astellas Pharma US INC | $171.11 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $156.92 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.15 | 2021-2025 | |
| Mylan Specialty L.P. | $94.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.50 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $31.73 | 2024-2025 | Gemtesa |
| Ardelyx, INC. | $31.17 | 2025 | Ibsrela |
| Pfizer INC. | $29.70 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.16 | 2021 | |
| Corcept Therapeutics | $18.66 | 2025 | Korlym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $17.26 | 2024 | |
| Dexcom, INC. | $14.68 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Paxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.